Tumor-induced CD8+ T-cell dysfunction in lung cancer patients

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Prado Garcia, Heriberto ^a   Romero Garcia, Susana ^a   Aguilar Cazares, Dolores ^a   Meneses Flores, Manuel ^a   Lopez Gonzalez, Jose Sullivan ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME; INTERLEUKIN 6; PERFORIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOLYSIS; DENDRITIC CELL; GENE EXPRESSION; HUMAN; IMMUNE DEFICIENCY; LUNG CANCER; LUNG EMPHYSEMA; LUNG FIBROSIS; LYMPHOCYTIC INFILTRATION; MELANOMA; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; SMOKING; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; METHODOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; PLEURAL EFFUSION, MALIGNANT;

EID: 84868704447     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/741741     Document Type: Review

References (121)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 2-s2.0-78049485263 10.1002/ijc.25516
3. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M., GLOBOCAN, 2008 V1. 2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010 Lyon, France International Agency for Research on Cancer.
4. Molina J. R., Yang P., Cassivi S. D., Schild S. E., Adjei A. A., Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings 2008 83 5 584 594 2-s2.0-44249086425 10.4065/83.5.584 (Pubitemid 351720831)
5. Alberg A. J., Ford J. G., Samet J. M., Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007 132 3 29S 55S 2-s2.0-34848837026 10.1378/chest.07-1347
6. Rabinovich G. A., Gabrilovich D., Sotomayor E. M., Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology 2007 25 267 296 2-s2.0-33947259319 10.1146/annurev.immunol.25.022106.141609 (Pubitemid 46697910)
7. Ding Z. C., Zhou G., Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clinical and Developmental Immunology 2012 2012 12 890178
8. Mantovani A., Allavena P., Sica A., Balkwill F., Cancer-related inflammation. Nature 2008 454 7203 436 444 2-s2.0-47949096781 10.1038/nature07205
9. O'Donnell R., Breen D., Wilson S., Djukanovic R., Inflammatory cells in the airways in COPD. Thorax 2006 61 5 448 454 2-s2.0-33646554531 10.1136/thx.2004.024463 (Pubitemid 43723331)
10. Lee J. M., Yanagawa J., Peebles K. A., Sharma S., Mao J. T., Dubinett S. M., Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Critical Reviews in Oncology/Hematology 2008 66 3 208 217 2-s2.0-43049142951 10.1016/j.critrevonc.2008.01.004
11. De Visser K. E., Eichten A., Coussens L. M., Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer 2006 6 1 24 37 2-s2.0-30144443269 10.1038/nrc1782 (Pubitemid 43053650)
12. Kim R., Emi M., Tanabe K., Cancer immunoediting from immune surveillance to immune escape. Immunology 2007 121 1 1 14 2-s2.0-34047220868 10.1111/j.1365-2567.2007.02587.x (Pubitemid 46537674)
13. Zitvogel L., Tesniere A., Kroemer G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Reviews Immunology 2006 6 10 715 727 2-s2.0-33748987908 10.1038/nri1936 (Pubitemid 44453458)
14. Cramer D. W., Finn O. J., Epidemiologic perspective on immune-surveillance in cancer. Current Opinion in Immunology 2011 23 2 265 271 2-s2.0-79953107374 10.1016/j.coi.2011.01.002
15. Arnson Y., Shoenfeld Y., Amital H., Effects of tobacco smoke on immunity, inflammation and autoimmunity. Journal of Autoimmunity 2010 34 3 J258 J265 2-s2.0-77649339064 10.1016/j.jaut.2009.12.003
16. Kumagai-Takei N., Maeda M., Chen Y., Asbestos induces reduction of tumor immunity., Clinical and Developmental Immunology 2011 2011 9 481439
17. Arenberg D., Chemokines in the biology of lung cancer. Journal of Thoracic Oncology 2006 1 4 287 288 2-s2.0-34247229740 10.1097/01243894- 200605000-00003 (Pubitemid 47163978)
18. Pakkala S., Ramalingam S. S., Lung cancer in HIV-positive patients. Journal of Thoracic Oncology 2010 5 11 1864 1871 2-s2.0-78149468193 10.1097/JTO.0b013e3181f387fd
19. Engsig F. N., Kronborg G., Larsen C. S., Pedersen G., Pedersen C., Gerstoft J., Obel N., Lung cancer in HIV patients and their parents: a Danish cohort study. BMC Cancer 2011 11, article 272 2-s2.0-79959427444 10.1186/1471-2407-11-272
20. Engels E. A., Biggar R. J., Hall H. I., Cross H., Crutchfield A., Finch J. L., Grigg R., Hylton T., Pawlish K. S., McNeel T. S., Goedert J. J., Cancer risk in people infected with human immunodeficiency virus in the United States. International Journal of Cancer 2008 123 1 187 194 2-s2.0-43949097900 10.1002/ijc.23487 (Pubitemid 351705208)
21. Jiménez C., Manrique A., Marqués E., Ortegz P., Loinaz C., Gómez R., Meneu J. C., Abradelo M., Moreno A., López A., Moreno E., Incidence and risk factors for the development of lung tumors after liver transplantation. Transplant International 2007 20 1 57 63 2-s2.0-33845659969 10.1111/j.1432-2277.2006.00397.x
22. Engels E. A., Pfeiffer R. M., Fraumen J. F. Jr., Spectrum of cancer risk among US solid organ transplant recipients. The Journal of the American Medical Association 2011 306 17 1891 1901
23. Heffner J. E., Diagnosis and management of malignant pleural effusions. Respirology 2008 13 1 5 20 2-s2.0-38049107782 10.1111/j.1440-1843.2007.01154.x
24. Prado-Garcia H., Aguilar-Cazares D., Flores-Vergara H., Mandoki J. J., Lopez-Gonzalez J. S., Effector, memory and naïve CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer 2005 47 3 361 371 2-s2.0-13844272823 10.1016/j.lungcan.2004.07.046 (Pubitemid 40248740)
25. Atanackovic D., Block A., De Weerth A., Faltz C., Hossfeld D. K., Hegewisch-Becker S., Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clinical Cancer Research 2004 10 8 2600 2608 2-s2.0-1942470399 10.1158/1078-0432.CCR-03-0239 (Pubitemid 38509132)
26. Pace E., Bruno T. F., Berenger B., Mody C. H., Melis M., Ferraro M., Tipa A., Bruno A., Profita M., Bonsignore G., Gjomarkaj M., Elevated expression of prostaglandin receptor and increased release of prostaglandin E2 maintain the survival of CD45RO+ T cells in the inflamed human pleural space. Immunology 2007 121 3 427 436 2-s2.0-34249337713 10.1111/j.1365-2567.2007.02593.x (Pubitemid 46817364)
27. Okamoto M., Hasegawa Y., Hara T., Hashimoto N., Imaizumi K., Shimokata K., Kawabe T., T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest 2005 128 6 4030 4035 2-s2.0-30344481411 10.1378/chest.128.6.4030 (Pubitemid 43062668)
28. Chen Y. M., Yang W. K., Ting C. C., Tsai W. Y., Yang D. M., Whang-Peng J., Perng R. P., Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. Chest 1997 112 4 960 966 2-s2.0-0030821151 (Pubitemid 27446315)
29. Thunnissen E., Kerr K. M., Herth F. J., The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012 76 1 1 18
30. Kirkwood J. M., Butterfield L. H., Tarhini A. A., Immunotherapy of cancer in 2012. CAA CancerJournal for Clinicians 2012 62 5 309 3335 10.3322/caac.20132
31. Yasumoto K., Hanagiri T., Takenoyama M., Lung cancer-associated tumor antigens and the present status of immunotherapy against Non-small-cell lung cancer. General Thoracic and Cardiovascular Surgery 2009 57 9 449 457 2-s2.0-70349249620 10.1007/s11748-008-0433-6
32. Restifo N. P., Dudley M. E., Rosenberg S. A., Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology 2012 12 4 269 2281
33. Gure A. O., Chua R., Williamson B., Gonen M., Ferrera C. A., Gnjatic S., Ritter G., Simpson A. J. G., Chen Y. T., Old L. J., Altorki N. K., Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clinical Cancer Research 2005 11 22 8055 8062 2-s2.0-28144457350 10.1158/1078-0432.CCR-05-1203 (Pubitemid 41698748)
34. Bria E., Visca P., Novelli F., Casini B., Diodoro M. G., Perrone-Donnorso R., Botti C., Sperduti I., Facciolo F., Milella M., Cecere F. L., Cognetti F., Mottolese M., Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. European Journal of Surgical Oncology 2008 34 5 593 598 2-s2.0-41949108454 10.1016/j.ejso.2007.06. 002 (Pubitemid 351514886)
35. Makita M., Hiraki A., Azuma T., Tsuboi A., Oka Y., Sugiyama H., Fujita S., Tanimoto M., Harada M., Yasukawa M., Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clinical Cancer Research 2002 8 8 2626 2631 2-s2.0-0036023425 (Pubitemid 34856350)
36. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., Elisseeva O. A., Oji Y., Kawakami M., Ikegame K., Hosen N., Yoshihira S., Wu F., Fujiki F., Murakami M., Masuda T., Nishida S., Shirakata T., Nakatsuka S. I., Sasaki A., Udaka K., Dohy H., Aozasa K., Noguchi S., Kawase I., Sugiyama H., Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Sciences of the United States of America 2004 101 38 13885 13890 2-s2.0-4644289323 10.1073/pnas.0405884101 (Pubitemid 39298502)
37. Ichiki Y., Takenoyama M., Mizukami M., So T., Sugaya M., Yasuda M., So T., Hanagiri T., Sugio K., Yasumoto K., Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. The Journal of Immunology 2004 172 8 4844 4850 2-s2.0-11144355077 (Pubitemid 38456407)
38. Hogan K. T., Eisinger D. P., Cupp S. B. III, Lekstrom K. J., Deacon D. D., Shabanowitz J., Hunt D. F., Engelhard V. H., Slingluff C. L., Ross M. M., The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Research 1998 58 22 5144 5150 2-s2.0-0032533507 (Pubitemid 28521175)
39. Echchakir H., Mami-Chouaib F., Vergnon I., Baurain J. F., Karanikas V., Chouaib S., Coulie P. G., A point mutation in the α -actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Research 2001 61 10 4078 4083 2-s2.0-0035872398 (Pubitemid 32720974)
40. Karanikas V., Colau D., Baurain J. F., Chiari R., Thonnard J., Gutierrez-Roelens I., Goffinet C., Van Schaftingen E., Weynants P., Boon T., Coulie P. G., High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Research 2001 61 9 3718 3724 2-s2.0-0035328852 (Pubitemid 32694985)
41. Takenoyama M., Baurain J. F., Yasuda M., So T., Sugaya M., Hanagiri T., Sugio K., Yasumoto K., Boon T., Coulie P. G., A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. International Journal of Cancer 2006 118 8 1992 1997 2-s2.0-33645239336 10.1002/ijc.21594
42. Van Der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van Den Eynde B., Knuth A., Boon T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 254 5038 1643 1647 2-s2.0-0026322151 (Pubitemid 21917508)
43. Wakabayashi O., Yamazaki K., Oizumi S., Hommura F., Kinoshita I., Ogura S., Dosaka-Akita H., Nishimura M., CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Science 2003 94 11 1003 1009 2-s2.0-0347506020 10.1111/j.1349-7006.2003.tb01392.x (Pubitemid 37521216)
44. Dieu-Nosjean M. C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., Rabbe N., Laurans L., Tartour E., De Chaisemartin L., Lebecque S., Fridman W. H., Cadranel J., Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. Journal of Clinical Oncology 2008 26 27 4410 4417 2-s2.0-52449102477 10.1200/JCO.2007.15.0284
45. Trojan A., Urosevic M., Dummer R., Giger R., Weder W., Stahel R. A., Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer. Lung Cancer 2004 44 2 143 147 2-s2.0-1842785866 10.1016/j.lungcan.2003. 11.004 (Pubitemid 38482046)
46. Yoshino I., Yano T., Murata M., Ishida T., Sugimachi K., Kimura G., Nomoto K., Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Research 1992 52 4 775 781 2-s2.0-0026552282
47. So T., Takenoyama M., Mizukami M., Ichiki Y., Sugaya M., Hanagiri T., Sugio K., Yasumoto K., Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Research 2005 65 13 5945 5952 2-s2.0-21344466748 10.1158/0008-5472.CAN-04-3787 (Pubitemid 40911201)
48. Baba T., Hanagiri T., Ichiki Y., Kuroda K., Shigematsu Y., Mizukami M., Sugaya M., Takenoyama M., Sugio K., Yasumoto K., Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Science 2007 98 11 1795 1802 2-s2.0-34748870776 10.1111/j.1349-7006.2007.00586.x (Pubitemid 47487918)
49. Winter H., van den Engel N. K., Rusan M., Active-specific immunotherapy for non-small cell lung cancer. Journal of Thoracic Disease 2011 3 2 105 114
50. Raez L. E., Fein S., Podack E. R., Lung cancer immunotherapy. Clinical Medicine & Research 2005 3 4 221 228 2-s2.0-34548058341
51. Weynants P., Thonnard J., Marchand M., Delos M., Boon T., Coulie P. G., Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. American Journal of Respiratory and Critical Care Medicine 1999 159 1 55 62 2-s2.0-0003026241 (Pubitemid 29036503)
52. Saijo Y., Hong X., Tanaka M., Tazawa R., Liu S. Q., Saijo K., Ohno T., Koike K., Ohkuda K., Satoh K., Nukiwa T., Autologous high-killing cytotoxic T lymphocytes against human lung cancer are induced using interleukin (IL)-1 β IL-2, IL-4, and IL-6: possible involvement of dendritic cells. Clinical Cancer Research 1999 5 5 1203 1209 2-s2.0-0032902310 (Pubitemid 29233239)
53. Nagata Y., Hanagiri T., Takenoyama M., Fukuyama T., Mizukami M., So T., Ichiki Y., Sugaya M., Sugio K., Yasumoto K., Identification of the HLA-Cw0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Clinical Cancer Research 2005 11 14 5265 5272 2-s2.0-22344450200 10.1158/1078-0432.CCR-04-2542 (Pubitemid 41003715)
54. So T., Takenoyama M., Ichiki Y., Mizukami M., So T., Hanagiri T., Sugio K., Yasumoto K., A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma. Cancer 2005 103 1 200 208 2-s2.0-10844227451 10.1002/cncr.20782 (Pubitemid 39665474)
55. Friedlein G., El Hage F., Vergnon I., Richon C., Saulnier P., Lécluse Y., Caignard A., Boumsell L., Bismuth G., Chouaib S., Mami-Chouaib F., Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. The Journal of Immunology 2007 178 11 6821 6827 2-s2.0-34249819661 (Pubitemid 46847407)
56. Barry M., Bleackley R. C., Cytotoxic T lymphocytes: all roads lead to death. Nature Reviews Immunology 2002 2 6 401 409 2-s2.0-0036595397 (Pubitemid 37328747)
57. Klebanoff C. A., Gattinoni L., Restifo N. P., CD8+ T-cell memory in tumor immunology and immunotherapy. Immunological Reviews 2006 211 214 224 2-s2.0-33745083070 10.1111/j.0105-2896.2006.00391.x (Pubitemid 43882974)
58. Berzofsky J. A., Terabe M., Oh S., Belyakov I. M., Ahlers J. D., Janik J. E., Morris J. C., Progress on new vaccine strategies for the immunotherapy and prevention of cancer. The Journal of Clinical Investigation 2004 113 11 1515 1525 2-s2.0-2942726511 10.1172/JCI200421926 (Pubitemid 39071672)
59. Williams M. A., Bevan M. J., Effector and memory CTL differentiation. Annual Review of Immunology 2007 25 171 192 2-s2.0-34247849183 10.1146/annurev.immunol.25.022106.141548 (Pubitemid 46697906)
60. Pagès F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., Cugnenc P. H., Trajanoski Z., Fridman W. H., Galon J., Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England Journal of Medicine 2005 353 25 2654 2666 2-s2.0-29144514645 10.1056/NEJMoa051424 (Pubitemid 41817714)
61. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P. H., Trajanoski Z., Fridman W. H., Pagès F., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 313 5795 1960 1964 2-s2.0-33749319703 10.1126/science.1129139 (Pubitemid 44498003)
62. Zhang L., Conejo-Garcia J. R., Katsaros D., Gimotty P. A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M. N., Rubin S. C., Coukos G., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine 2003 348 3 203 213 2-s2.0-0037448353 10.1056/NEJMoa020177 (Pubitemid 36077915)
63. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., Mizuno T., Aokage K., Saijo N., Nishiwaki Y., Gemma A., Kudoh S., Ochia A., Predominant infiltration of macrophages and CD8+ T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008 113 6 1387 1395 2-s2.0-53149083361 10.1002/cncr.23712
64. Al-Shibli K. I., Donnem T., Al-Saad S., Persson M., Bremnes R. M., Busund L. T., Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clinical Cancer Research 2008 14 16 5220 5227 2-s2.0-52649163840 10.1158/1078-0432.CCR-08-0133
65. Ruffini E., Asioli S., Filosso P. L., Lyberis P., Bruna M. C., Macrì L., Daniele L., Oliaro A., Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. The Annals of Thoracic Surgery 2009 87 2 365 372 2-s2.0-58249134743 10.1016/j.athoracsur.2008.10.067
66. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., Itoh T., Ohbuchi T., Kondo S., Katoh H., Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. British Journal of Cancer 2006 94 2 275 280 2-s2.0-31444439350 10.1038/sj.bjc.6602934 (Pubitemid 43151547)
67. Lucivero G., Pierucci G., Bonomo L., Lymphocyte subsets in peripheral blood and pleural fluid. European Respiratory Journal 1988 1 4 337 340 2-s2.0-0023939643
68. de Chaisemartin L., Goc J., Damotte D., Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Research 2011 71 20 6391 6399
69. Chen Y. M., Ting C. C., Peng J. W., Yang W. K., Yang K. Y., Tsai C. M., Perng R. P., Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 versus interleukin-2. Journal of Interferon and Cytokine Research 2000 20 1 31 39 2-s2.0-0033969272 10.1089/107999000312711 (Pubitemid 30067487)
70. Thomas D. A., Massagué J., TGF- β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005 8 5 369 380 2-s2.0-27644457376 10.1016/j.ccr.2005.10.012 (Pubitemid 41579832)
71. López-González J. S., Aguilar-Cázares D., Prado-García H., Nieto-Rodríguez A., Mandoki J. J., Avila-Moreno F., Rivera R. M., Chavarría-Garcés J., Lack of correlation between growth inhibition by TGF- β and the percentage of cells expressing type II TGF- β receptor in human non-small cell lung carcinoma cell lines. Lung Cancer 2002 38 2 149 158 2-s2.0-0036838158 10.1016/S0169-5002(02)00177-0 (Pubitemid 35154379)
72. Croci D. O., Zacarías Fluck M. F., Rico M. J., Matar P., Rabinovich G. A., Scharovsky O. G., Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunology, Immunotherapy 2007 56 11 1687 1700 2-s2.0-34548162341 10.1007/s00262-007-0343-y (Pubitemid 47313090)
73. Weng N. P., Liu K., Catalfamo M., Li Y., Henkart P. A., IL-15 is a growth factor and an activator of CD8 memory T cells. Annals of the New York Academy of Sciences 2002 975 46 56 2-s2.0-0036960253 (Pubitemid 36131113)
74. Baxevanis C. N., Voutsas I. F., Tsitsilonis O. E., Gritzapis A. D., Sotiriadou R., Papamichail M., Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. The Journal of Immunology 2000 164 7 3902 3912 2-s2.0-0034176817 (Pubitemid 30169850)
75. Chen Y. Q., Shi H. Z., Qin X. J., Mo W. N., Liang X. D., Huang Z. X., Yang H. B., Wu C., CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. American Journal of Respiratory and Critical Care Medicine 2005 172 11 1434 1439 2-s2.0-30344474268 10.1164/rccm.200504-588OC (Pubitemid 43069817)
76. Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H., Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Research 2001 61 12 4766 4772 2-s2.0-0035874949 (Pubitemid 32691889)
77. DeLong P., Carroll R. G., Henry A. C., Tanaka T., Ahmad S., Leibowitz M. S., Sterman D. H., June C. H., Albelda S. M., Vonderheide R. H., Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biology and Therapy 2005 4 3 342 346 2-s2.0-24944580634 (Pubitemid 41351297)
78. Tao H., Mimura Y., Aoe K., Kobayashi S., Yamamoto H., Matsuda E., Okabe K., Matsumoto T., Sugi K., Ueoka H., Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 2012 75 1 95 101 2-s2.0-79959555349 10.1016/j.lungcan.2011. 06.002
79. Esendagli G., Bruderek K., Goldmann T., Busche A., Branscheid D., Vollmer E., Brandau S., Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008 59 1 32 40 2-s2.0-37549028767 10.1016/j.lungcan.2007.07.022
80. Prado-Garcia H., Aguilar-Cazares D., Meneses-Flores M., Morales-Fuentes J., Lopez-Gonzalez J. S., Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression. Cancer Immunology, Immunotherapy 2008 57 3 325 336 2-s2.0-37349037860 10.1007/s00262-007-0372-6 (Pubitemid 350295375)
81. Broderick L., Brooks S. P., Takita H., Baer A. N., Bernstein J. M., Bankert R. B., IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clinical Immunology 2006 118 2-3 159 169 2-s2.0-32044452015 10.1016/j.clim.2005.09.008 (Pubitemid 43199654)
82. Kilinc M. O., Aulakh K. S., Nair R. E., Jones S. A., Alard P., Kosiewicz M. M., Egilmez N. K., Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. The Journal of Immunology 2006 177 10 6962 6973 2-s2.0-33750802413 (Pubitemid 44715062)
83. Dong H., Strome S. E., Salomao D. R., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine 2002 8 793 800
84. Blank C., Gajewski T. F., Mackensen A., Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunology, Immunotherapy 2005 54 4 307 314 2-s2.0-13744253833 10.1007/s00262-004-0593-x (Pubitemid 40238924)
85. Freeman G. J., Wherry E. J., Ahmed R., Sharpe A. H., Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. The Journal of Experimental Medicine 2006 203 10 2223 2227 2-s2.0-33749324118 10.1084/jem.20061800 (Pubitemid 44498355)
86. Ahmadzadeh M., Johnson L. A., Heemskerk B., Wunderlich J. R., Dudley M. E., White D. E., Rosenberg S. A., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009 114 8 1537 1544 2-s2.0-70349569569 10.1182/blood-2008-12- 195792
87. Zhang Y., Huang S., Gong D., Qin Y., Shen Q., Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cellular and Molecular Immunology 2010 7 5 389 395 2-s2.0-77957664158 10.1038/cmi.2010.28
88. Brahmer J. R., Drake C. G., Wollner I., Powderly J. D., Picus J., Sharfman W. H., Stankevich E., Pons A., Salay T. M., McMiller T. L., Gilson M. M., Wang C., Selby M., Taube J. M., Anders R., Chen L., Korman A. J., Pardoll D. M., Lowy I., Topalian S. L., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology 2010 28 19 3167 3175 2-s2.0-77954899030 10.1200/JCO.2009.26.7609
89. Kontani K., Sawai S., Hanaoka J., Tezuka N., Inoue S., Fujino S., Involvement of granzyme B and perforin in suppressing nodal metastasis of cancer cells in breast and lung cancers. European Journal of Surgical Oncology 2001 27 2 180 186 2-s2.0-0034946389 10.1053/ejso.2000.1060 (Pubitemid 32621732)
90. Seder R. A., Ahmed R., Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nature Immunology 2003 4 9 835 842 2-s2.0-0041381363 10.1038/ni969 (Pubitemid 37098653)
91. Appay V., Dunbar P. R., Callan M., Klenerman P., Gillespie G. M. A., Papagno L., Ogg G. S., King A., Lechner F., Spina C. A., Little S., Havlir D. V., Richman D. D., Gruener N., Pape G., Waters A., Easterbrook P., Salio M., Cerundolo V., McMichael A. J., Rowland-Jones S. L., Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Medicine 2002 8 4 379 385 2-s2.0-0036109159 10.1038/nm0402-379 (Pubitemid 34407033)
92. Chen Y. M., Yang W. K., Whang-Peng J., Tsai W. Y., Hung Y. M., Yang D. M., Lin W. C., Perng R. P., Ting C. C., Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. Journal of Immunotherapy 1997 20 5 354 364 2-s2.0-0031463668 (Pubitemid 28011531)
93. Kim H. R., Hwang K. A., Park S. H., Kang I., IL-7 and IL-15: biology and roles in T-cell immunity in health and disease. Critical Reviews in Immunology 2008 28 4 325 339 2-s2.0-55349112529
94. Chen Y. M., Tsai C. M., Whang-Peng J., Perng R. P., Double signal stimulation was required for full recovery of the autologous tumor-killing effect of effusion-associated lymphocytes. Chest 2002 122 4 1421 1427 2-s2.0-0036431733 10.1378/chest.122.4.1421 (Pubitemid 35339562)
95. Hoffmann T. K., Dworacki G., Tsukihiro T., Meidenbauer N., Gooding W., Johnson J. T., Whiteside T. L., Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clinical Cancer Research 2002 8 8 2553 2562 2-s2.0-0036023415 (Pubitemid 34856339)
96. Kuss I., Donnenberg A. D., Gooding W., Whiteside T. L., Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. British Journal of Cancer 2003 88 2 223 230 2-s2.0-0037468122 10.1038/sj.bjc.6600694 (Pubitemid 36255840)
97. Albers A. E., Schaefer C., Visus C., Gooding W., DeLeo A. B., Whiteside T. L., Spontaneous apoptosis of tumor-specific tetramer+ CD8 + T lymphocytes in the peripheral circulation of patients with head and neck cancer. Head and Neck 2009 31 6 773 781 2-s2.0-67049156009 10.1002/hed.21031
98. Caras I., Grigorescu A., Stavaru C., Radu D. L., Mogos I., Szegli G., Salageanu A., Evidence for immune defects in breast and lung cancer patients. Cancer Immunology, Immunotherapy 2004 53 12 1146 1152 2-s2.0-8644265838 10.1007/s00262-004-0556-2 (Pubitemid 39506403)
99. Wieckowski E. U., Visus C., Szajnik M., Szczepanski M. J., Storkus W. J., Whiteside T. L., Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. The Journal of Immunology 2009 183 6 3720 3730 2-s2.0-70349315105 10.4049/jimmunol.0900970
100. Maher S., Toomey D., Condron C., Bouchier-Hayes D., Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunology and Cell Biology 2002 80 2 131 137 2-s2.0-0036215202 10.1046/j.1440-1711.2002.01068.x (Pubitemid 34298085)
101. Prado-Garcia H., Romero-Garcia S., Morales-Fuentes J., Aguilar-Cazares D., Lopez-Gonzalez J. S., Activation-induced cell death of memory CD8+ T cells from pleural effusion of lung cancer patients is mediated by the type II Fas-induced apoptotic pathway. Cancer Immunology Immunotherapy 2012 61 7 1065 1080
102. Toomey D., Smyth G., Condron C., Kelly J., Byrne A. M., Kay E., Conroy R. M., Broe P., Bouchier-Hayes D., Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: no association with prognosis identified in 3-year follow-up. International Journal of Cancer 2003 103 3 408 412 2-s2.0-0037454777 10.1002/ijc.10836 (Pubitemid 36076435)
103. Restifo N. P., Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nature Medicine 2000 6 5 493 495 2-s2.0-0034080750 10.1038/74955 (Pubitemid 30305889)
104. Lu B., Finn O. J., T-cell death and cancer immune tolerance. Cell Death and Differentiation 2008 15 1 70 79 2-s2.0-37349039029 10.1038/sj.cdd.4402274 (Pubitemid 350286174)
105. Zaks T. Z., Chappell D. B., Rosenberg S. A., Restifo N. P., Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. The Journal of Immunology 1999 162 6 3273 3279 2-s2.0-0033559564 (Pubitemid 29313574)
106. Gati A., Guerra N., Gaudin C., Da Rocha S., Escudier B., Lécluse Y., Bettaieb A., Chouaib S., Caignard A., CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling. Cancer Research 2003 63 21 7475 7482 2-s2.0-0242694876 (Pubitemid 37413491)
107. Li J. H., Rosen D., Sondel P., Berke G., Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology 2002 105 3 267 277 2-s2.0-0036231207 10.1046/j.1365-2567.2002.01380.x (Pubitemid 34304403)
108. Radoja S., Saio M., Frey A. B., CD8+ tumor-infiltrating lymphocytes are primed for fas-mediated activation-induced cell death but are not apoptotic in situ. The Journal of Immunology 2001 166 10 6074 6083 2-s2.0-0035873472 (Pubitemid 32440734)
109. Bouillet P., O'Reilly L. A., CD95, BIM and T cell homeostasis. Nature Reviews Immunology 2009 9 7 514 519 2-s2.0-67649884532 10.1038/nri2570
110. Fas S. C., Baumann S., Krueger A., Frey C. R., Schulze-Bergkamen H., Brenner D., Stumpf C., Kappes K., Krammer P. H., In vitro generated human memory-like T cells are CD95 type II cells and resistant towards CD95-mediated apoptosis. European Journal of Immunology 2006 36 11 2894 2903 2-s2.0-33751243926 10.1002/eji.200635925 (Pubitemid 44782563)
111. Batra R. K., Lin Y., Sharma S., Dohadwala M., Luo J., Pold M., Dubinett S. M., Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I κ B kinase-dependent mechanism. Cancer Research 2003 63 3 642 646 2-s2.0-0037309811 (Pubitemid 36158142)
112. Das T., Sa G., Paszkiewicz-Kozik E., Hilston C., Molto L., Rayman P., Kudo D., Biswas K., Bukowski R. M., Finke J. H., Tannenbaum C. S., Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways. The Journal of Immunology 2008 180 7 4687 4696 2-s2.0-44449160500
113. Spooner R., Yilmaz Ö., The role of reactive-oxygen-species in microbial persistence and inflammation. International Journal of Molecular Sciences 2011 12 1 334 352 2-s2.0-79251643306 10.3390/ijms12010334
114. Norell H., Da Palma T. M., Lesher A., Kaur N., Mehrotra M., Naga O. S., Spivey N., Olafimihan S., Chakraborty N. G., Voelkel-Johnson C., Nishimura M. I., Mukherji B., Mehrotra S., Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-127-35-reactive T cells from activation-induced cell death. Cancer Research 2009 69 15 6282 6289 2-s2.0-68049133176 10.1158/0008-5472.CAN-09-1176
115. Takahashi A., Hanson M. G. V., Norell H. R., Havelka A. M., Kono K., Malmberg K. J., Kiessling R. V. R., Preferential cell death of CD8+ effector memory (CCR7 -CD45RA-) T cells by hydrogen peroxide-induced oxidative stress. The Journal of Immunology 2005 174 10 6080 6087 2-s2.0-18644362802 (Pubitemid 40663796)
116. Zarozinski C. C., McNally J. M., Lohman B. L., Daniels K. A., Welsh R. M., Bystander sensitization to activation-induced cell death as a mechanism of virus-induced immune suppression. Journal of Virology 2000 74 8 3650 3658 2-s2.0-0034111526 10.1128/JVI.74.8.3650-3658.2000 (Pubitemid 30180309)
117. Antoniou K. M., Ferdoutsis E., Bouros D., Interferons and their application in the diseases of the lung. Chest 2003 123 1 209 216 2-s2.0-0037249039 10.1378/chest.123.1.209 (Pubitemid 36126734)
118. Castagneto B., Zai S., Mutti L., Lazzaro A., Ridolfi R., Piccolini E., Ardizzoni A., Fumagalli L., Valsuani G., Botta M., Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 2001 31 2-3 303 310 2-s2.0-0035139422 10.1016/S0169-5002(00)00192-6 (Pubitemid 32107025)
119. Timoshenko A. V., Lan Y., Gabius H. J., Lala P. K., Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination: effects on tumour growth, capillary leakage and nitric oxide (NO) production. European Journal of Cancer 2001 37 15 1910 1920 2-s2.0-0034813262 10.1016/S0959-8049(01)00156-3 (Pubitemid 32913320)
120. Ratto G. B., Zino P., Mirabelli S., A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996 78 2 244 251 (Pubitemid 26234566)
121. Ratto G. B., Cafferata M. A., Scolaro T., Bruzzi P., Alloisio A., Costa R., Spessa E., Semino C., Melioli G., Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. Journal of Immunotherapy 2000 23 1 161 167 2-s2.0-0033973860 10.1097/00002371-200001000-00019 (Pubitemid 30079837)